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Abstract
Despite being a very common problem after birth, consensus on how to manage low glucose concentrations in
the first 48 h of life has been difficult to establish and remains a debated issue. One of the reasons for this is that
few studies have provided the type of data needed to establish a definitive approach agreed upon by all. However,
some recent publications have provided much needed primary data to inform this debate. These publications have
focused on aspects of managing low blood glucose concentrations in the patients most at-risk for asymptomatic
hypoglycemia—those born late-preterm, large for gestational age, small for gestational age, or growth restricted,
and those born following a pregnancy complicated by diabetes mellitus. The goal of this review is to discuss
specific aspects of this new research. First, we focus on promising new data testing the role of buccal dextrose gel
in the management of asymptomatic neonatal hypoglycemia. Second, we highlight some of the clinical implications of
a large, prospective study documenting the association of specific glycemic patterns with neurodevelopmental
outcomes at two years of age.
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Background
Hypoglycemia is one of the most frequently encountered
problems in the first 48 h of life, and low glucose con-
centrations are perhaps the most common biochemical
abnormality seen by providers caring for newborns.
Unfortunately, the optimal strategy for managing this
problem remains elusive and is a matter of differing
interpretations of the available literature [1–8]. New data
to inform the optimal management of these newborns is
urgently needed [9]. Especially controversial is the man-
agement of asymptomatic but at-risk newborns, most
commonly those with a history or physical exam consist-
ent with being born late-preterm, large for gestational
age (LGA), small for gestational age (SGA), or growth
restricted, or an infant of a diabetic mother (IDM). The
reason for this controversy is that numerous studies have
shown that, with the exception of the LGA group, these
newborns have worse neurodevelopmental outcomes than
healthy term babies [10–13] and that in some of these
groups, worse neurodevelopmental outcomes are associated
with the presence of neonatal hypoglycemia [12]. To date,
no study has shown that preventing or treating the
hypoglycemia in these groups leads to better outcomes,
making it uncertain whether hypoglycemia has a causal role
in producing the worse outcomes. In fact, the statement
made by the AAP in 1993 remains accurate today, “… there
is no evidence that asymptomatic hypoglycemic infants will
benefit from treatment [14].” The goal of this review is to
discuss recent primary research that has added important
new data to consider when devising strategies to manage
this group of newborns. These recent data hold promise
for optimizing our approach to managing neonatal
hypoglycemia, especially in the at-risk groups noted above.
Asymptomatic neonatal hypoglycemia
The newborns most at risk for, and most frequently
screened for, asymptomatic hypoglycemia include late
preterm, LGA, SGA, and/or intrauterine growth
restricted (IUGR) infants, and IDMs [4]. Frequent milk
feedings with repeated glucose measurements is the current
standard treatment for asymptomatic hypoglycemia in
these groups of patients [4]. This approach allows mothers
and babies to remain together, provides nutrient substrates
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to support gluconeogenesis as it develops, and ensures that
the hypoglycemia resolves. If hypoglycemia persists despite
frequent milk feedings, a continuous intravenous dextrose
infusion may be indicated. The following approach to the
rate of dextrose infusion for asymptomatic hypoglycemia
can be considered. A dextrose infusion rate of 3–5 mg/kg/
min can be used for IDMs, as this avoids overstimulation of
insulin secretion and accounts for the larger fat mass that
these infants have. A dextrose infusion rate of 4–7 mg/kg/
min can be used for most term and near term infants. A
dextrose infusion rate of 6–8 mg/kg/min often is necessary
in IUGR infants. This accounts for their greater brain/body
weight ratio and physiological observations made in animal
models of IUGR of both increased peripheral insulin sensi-
tivity and increased insulin secretion as their postnatal
physiology is normalized and insulin-suppressive catechol-
amine secretion is reduced [15–20]. Glucose concentrations
must be followed closely as some of these IUGR infants,
especially those very preterm, also can have hyperglycemia,
due to reduced insulin secretion capacity, diminished
muscle mass for glucose disposal, and persistent glucose
production [17, 18, 20–30]. A continuous intravenous
dextrose infusion, usually preceded by an intravenous dex-
trose bolus (200 mg/kg given over 5 min), also is indicated
if these newborns develop symptomatic hypoglycemia. In
fact, partial or complete resolution of the symptoms with
correction of glucose concentrations is considered proof
that the symptoms were caused by the low glucose concen-
trations [31]. Intravenous dextrose infusions, however, are
not benign; they cause discomfort and stress due to the
placement of an intravenous catheter, admission to a NICU,
and physical separation of the mother and newborn which
risks impairing the timely and successful establishment of
breastfeeding and bonding. Preventing these complications
of intravenous dextrose infusions, while safely managing
asymptomatic low glucose concentrations, has many poten-
tial benefits.
Dextrose gel
To this end, Harris, et al. undertook a large, randomized,
placebo-controlled, double-blinded study of buccal dex-
trose gel for the treatment of asymptomatic hypoglycemia,
defined as a plasma glucose less than 47 mg/dL
(2.6 mmol/L) irrespective of postnatal age [32]. The dex-
trose gel (200 mg/kg) or placebo gel was massaged into
the infant’s dried buccal mucosa and the infant was
encouraged to feed. If the baby still had a low glucose con-
centration 30 min after gel administration, or if the baby
developed recurrent hypoglycemia, the treatment with
study gel continued for a total of six doses over 48 h.
The specific characteristics of the populations studied
included late preterm (35–36 weeks gestational age),
LGA (>90th percentile or >4500 g), SGA/IUGR (<10th
percentile or <2500 g), and IDM newborns. In these
groups dextrose gel decreased the number of episodes
of hypoglycemia, decreased the recurrence rate of
hypoglycemia, increased exclusive breastfeeding rates at
discharge, and decreased the need for admission to the
neonatal intensive care (NICU) unit to treat hypoglycemia.
The number of newborns needed to treat to prevent one
admission to the NICU for hypoglycemia was only eight. It
is important to note that in this study the newborns,
regardless of randomization, were still managed with
aggressive oral feeding (mostly breastmilk) to treat
hypoglycemia. There were no adverse events reported
and continuous interstitial glucose monitoring (to
which the care providers were blinded) did not identify
more frequent, clinically unrecognized episodes of
rebound or recurrent hypoglycemia in the dextrose gel
group, thereby establishing short term safety. Of note,
overall admission rates to the NICU for all causes were
not statistically significantly different between groups
(38 % in the dextrose gel group vs. 46 % with placebo
gel). The most likely cause of the lack of effect on over-
all NICU admission rates, despite the reduction in
NICU admissions to treat hypoglycemia, is simply that
the sample size was too small to show a difference in
this secondary outcome.
Despite these encouraging short term results, there
was some concern that the dextrose gel treatment might
have adversely impacted long term neurodevelopmental
outcomes. Reasons for concern included a potential
delay in definitive treatment with intravenous dextrose,
rapid overcorrection and iatrogenic hyperglycemia, and
increased variability in glucose concentrations [33, 34].
Information from continuous glucose monitoring sensors
(CGMS), which was blinded to the caregivers, was re-
assuring regarding these concerns. When the researchers
looked at the CGMS data, however, they found that the
time to achieve an interstitial glucose concentration
greater than 47 mg/dL (2.6 mmol/L) with dextrose gel
was as rapid as has been reported for correction with
intravenous dextrose given at 8 mg/kg/min–about twenty
minutes [35]. CGMS data also showed that rebound
hypoglycemia was rare in both groups and the incidence
of recurrent hypoglycemia was less in the dextrose gel
group. While these data support the safety and efficacy of
he dextrose gel established by intermittent glucose
sampling, CGMS was only used in a subset of the pa-
tients in this study. Therefore, it is important that two
year outcomes have recently been published [36]. 78 %
of the original hypoglycemic cohort was available for
assessment of outcomes at two years of age. Fortu-
nately, there were no differences between the dextrose
gel group and placebo group for neurosensory impair-
ment, processing difficulties, or secondary growth and
developmental outcomes. The high rates of abnormal
outcomes in both groups is concerning and should
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prompt further research into optimal management of
these patients [36].
When considering the adoption of dextrose gel into
clinical practice, it must be remembered that although
the study was quite large and included a broad represen-
tation of the main at-risk groups, it was a single center
study. A multi-centered trial confirming these results
would broaden the applicability of this therapy. This
issue is highlighted by the results for improved rates of
exclusive breast feeding at two weeks of age [32]. The
rates of exclusive breastfeeding at this age are quite high
in this New Zealand population. Whether this benefit
would be replicated in populations with higher or lower
rates of breast feeding is unknown. However, if a new
trial included hospitals without a NICU, the benefits of
dextrose gel might also include lower transfer rates of
these patients to hospitals that have intensive care cap-
abilities. It also is important to note that the definition
of hypoglycemia and treatment cut-off were both 47 mg/
dL (2.6 mmole/L), irrespective of gestational and postnatal
age. This definition does not take into account the age
related changes in mean and lower limits of normal glu-
cose concentrations that occur in the first days of life [37].
The definition of hypoglycemia, screening frequency, and
screening duration also may vary from what is used in
some clinical practices [4, 8]. Clinicians should ensure that
they have accounted for these differences when consid-
ering adoption of dextrose gel into clinical practice.
Not only was screening for hypoglycemia quite fre-
quent, in this study the clinicians used a very reliable
point of care device. This device uses the gold standard
glucose oxidase method for measurement of plasma
glucose concentrations, which is much more accurate
than bedside glucometers [38]. Glucose concentrations
were measured at one hour of age, then before feeds
every 3–4 h for the first 24 h of age, and then before
feeds every 6–8 h for the next 24 h. This protocol iden-
tified 46 % of the enrolled patients as hypoglycemic,
who were included in the study. This relatively high
incidence of neonatal hypoglycemia in this population
likely is due to the rigorous and frequent screening
protocol, the method used to measure glucose concen-
trations, the higher glucose concentration threshold
that was used to define hypoglycemia compared to
other published guidelines [4], and a definition of
hypoglycemia that does not exclude infants who have
low glucose concentrations during the normal physio-
logical nadir that occurs in normal infants in the first
hours of life [7, 37].
Other important considerations are that the dextrose gel
treatment was tested in infants who were at-risk for
hypoglycemia but were otherwise well-appearing and
asymptomatic [32]. The results cannot be applied to infants
with severe, symptomatic, and recurrent hypoglycemia,
and/or if the infant is not in one of the at-risk groups stud-
ied. Furthermore, the dextrose gel did not eliminate the
need for intravenous dextrose therapy. Over 10 % of infants
treated with dextrose gel in this study had an episode of
rebound hypoglycemia and over 20 % had an episode of
recurrent hypoglycemia after a documented normal glucose
concentration. While these rates were similar to or better
than those in the placebo group, practitioners should not
be using this therapy without close follow up of subsequent
glucose concentrations, clinical signs of hypoglycemia, and
documentation of resolution of the hypoglycemia [4, 8].
Despite these limitations, the therapy appears safe and
effective at preventing NICU admissions for hypoglycemia
and it may be appropriate for some hospitals to adopt into
clinical practice. Indeed, such efforts are already being
described with promising results [39, 40]. Making guide-
lines for managing low glucose concentrations in the first
days of life safe and easy to follow, while at the same time
promoting increased maternal-infant interactions and
increased breastfeeding rates, is critical for all practitioners
caring for newborns. Buccal dextrose gel appears to have a
promising role in achieving these goals and caregivers can
be more confident that the early benefits of dextrose gel are
not associated with worse two year neurodevelopmental
outcomes [36].
Continuous glucose monitoring
Another interesting feature of the dextrose gel study is
the use of CGMS to continuously monitor interstitial
glucose concentrations. One important observation is
that many episodes of hypoglycemia, documented by
both blood obtained per their low glucose concentration
screening protocol and CGMS measurements, resolved
spontaneously, and were not associated with bedside
nursing observations of clinical signs that might be
interpreted as symptoms of hypoglycemia. Thus, while
CGMS remains a research tool, this observation demon-
strates the potential for CGMS to reduce unnecessary
treatment for hypoglycemia. For example, CGMS may
identify patients in whom their low glucose concentra-
tions have resolved prior to commencement of interven-
tions. However, there also is the potential for CGMS to
increase unnecessary treatment for hypoglycemia. For
the clinician, CGMS or any other method that continu-
ously provides glucose concentration data will present a
challenge to the way we think about hypoglycemia.
Instead of an intermittent variable, caregivers will be
provided with a continuous variable, analogous to the
transition from intermittent blood gas measurements to
continuous pulse oximetry for monitoring blood oxygen-
ation. Furthermore, CGMS in this population, as well as
in more preterm newborns, will identify numerous epi-
sodes of low glucose concentrations that are not identi-
fied by intermittent routine blood sampling [41, 42]. In
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fact, in the populations studied by Harris, et. al., 81 % of all
episodes of hypoglycemia were recognized with CGMS
only and not by routine clinical blood sampling [42]. There
is very little information about the clinical significance of
these episodes for long term outcomes, including which
should be treated and whether such treatment would
improve outcomes. It is possible, therefore, that identifying
these episodes of hypoglycemia with CGMS could increase
overtreatment of clinically insignificant low glucose
concentrations. This risk might outweigh the benefits of
documenting more episodes of low glucose concentra-
tions and avoiding treatment of those that resolve spon-
taneously, as well as the early detection of serious,
recurrent hypoglycemia in patients with hyperinsuline-
mic hypoglycemia and other metabolic disorders [43].
The uncertainty regarding the balance of the risks and
benefits of using CGMS or similar devices for the con-
tinuous monitoring of neonatal glucose concentrations
in this population highlights the need for further stud-
ies in this area. Such studies will have to be designed
to clarify relationships between continuous glucose
concentrations, symptomatic hypoglycemia, responses
to treatment, associated medical conditions, and neu-
rodevelopmental outcomes.
Identifying and treating asymptomatic
hypoglycemic newborns
There is very little evidence to inform how often glucose
concentrations should be screened in the asymptomatic
at-risk newborn or the glucose concentration threshold
one should use for treatment. Also unknown are the
degree and duration of hypoglycemia necessary to cause
permanent neurological injury [9]. Especially important
is the question of how to identify the rare infant in
which asymptomatic hypoglycemia is the first presenta-
tion of a rare and persistent disorder of hypoglycemia
such as congenital hyperinsulinemic hypoglycemia, fatty
acid oxidation disorders, hypopituitarism, and glycogen
storage diseases [8]. In 2011 the AAP published clinical
guidelines to address some of these concerns, with spe-
cial attention to management of hypoglycemia in the
first 24 h of life [4]. They suggested that late preterm,
LGA, SGA/IUGR, and IDM newborns should be fed by
one hour of age and have their glucose checked 30 min
after the feeding. Glucose monitoring should then con-
tinue before feeds through 12 h of age for LGA and
IDM patients as long as pre-feed plasma glucose con-
centrations remain greater than 40 mg/dL (2.2 mmol/L).
It was suggested that late preterm and SGA infants
should be screened before feeds for 24 h. In 2012 Harris,
et al. published the incidence of hypoglycemia during
this same 24 h period, again defining as plasma glucose
concentrations <47 mg/dL (2.6 mmol/L) irrespective of
age in this same group of newborns [44]. They used a
more frequent screening protocol, measuring glucose
concentrations one hour after birth and then before
feeds every 3–4 h for the first 24 h of life, but also added
screening every 3–8 h for the second 24 h of life. While
the incidence of hypoglycemia in this population was
quite high (51 %), more important were the observations
that, of the patients with hypoglycemia, 37 % had their
first episode after having had three plasma glucose con-
centrations greater than 47 mg/dL (2.6 mmol/L) and
6 % had their first episode after 24 h of age [44].
Another important observation in this study was that
there were no differences among the at-risk groups stud-
ied in the incidence or timing of the hypoglycemia.
While the long term clinical significance of these epi-
sodes of hypoglycemia, whether first identified in the
first 24 h or later, remains unclear, it may be a reason-
able approach to simplify screening protocols so that
screening frequency and duration are the same for all at-
risk groups [44, 45].
The definition of hypoglycemia and the threshold
for treatment and continued management are contro-
versial as well. A plasma glucose concentration of
47 mg/dL (2.6 mmol/L) was used in multiple studies
by Harris, et al. as their threshold for diagnosis and
treatment [32, 34, 36, 42, 44]. The 2011 guideline by
the AAP states that once hypoglycemia is identified,
treatment should commence with feeding or intraven-
ous dextrose infusion and a target plasma glucose con-
centration of greater than 45 mg/dL (2.5 mmol/L)
should be used [4]. In 2015 the Pediatric Endocrine
Society published new recommendations regarding the
management of hypoglycemia in newborns [8]. While
the main goals of these recommendations were to help
clinicians distinguish between physiologically low glu-
cose concentrations in normal newborns and those
that persist beyond the first 48 h of life and might
place the infant at risk for neurological injury, this
group made the recommendation that in the first 48 h
of life the target threshold plasma glucose concentration
for treatment should be 50 mg/dL (2.8 mmol/L). This
group also made the case that neurogenic symptoms
occur in newborns below the same glucose concentrations
as in adults (55–65 mg/dL [3.1–3.6 mmol/L]) [7, 8]. Thus,
they also make the recommendation that in specific
patients higher glucose target thresholds of 60 mg/dL
(3.3 mmol/L) and 70 mg/dL (3.9 mmol/L) should be used
[8]. To date, there is no data to rationally define selection
of any one of these lower limit threshold glucose concen-
tration values, in terms of which treatment to use, acute
risks vs. benefits, or impact on longer term neurodevelop-
mental outcomes.
The variability among the recommendations of these
different publications reflects the need for further
research. A recent publication from the same group that
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performed the dextrose gel study has provided some
data [34], but this was not a study that randomized new-
borns to different glucose treatment thresholds. How-
ever, what they found was that, regardless of treatment
with or without the dextrose gel, asymptomatic patients
in the main at-risk groups (late preterm, LGA, SGA/
IUGR, IDM) had similar neurodevelopmental outcomes
at two years of age whether they had hypoglycemia
(<47 mg/dL [2.6 mmol/L]) identified in the first seven
days of life or not [34]. This assumes that the infants
were screened in the first 48 h by the rigorous protocol
described above and that when identified, the newborns
were treated to achieve or exceed a target plasma glu-
cose concentration of 47 mg/dL (2.6 mmol/L). The main
conclusion that one can make from these data is that in
this specific patient population with frequent screening
and identification of hypoglycemia, using a target plasma
glucose concentration of 47 mg/dL (2.6 mmol/L) results
in neurodevelopmental outcomes similar to those at-risk
patients who did not have an episode of hypoglycemia
[34]. However, it cannot be emphasized enough that the
plasma glucose concentration defining hypoglycemia was
arbitrarily set at 47 mg/dL (2.6 mmol/L) and does not take
into account evolution of glucose concentrations and their
variability in the first week of life [7]. A plasma glucose con-
centration of 47 mg/dL (2.6 mmol/L) will likely be less clin-
ically relevant at 6 h of age compared to four days of age,
when low glucose concentrations should have increased
spontaneously [7].
In the study by McKinlay, et al. the rate of neurodeve-
lopmental delay was not different in the group that ex-
perienced a hypoglycemic event (33 %) compared to the
group that did not (36 %) [34]. But these rates are high,
and some might argue that the threshold for treatment
should be even higher than 47 mg/dL (2.6 mmol/L).
However, the lack of two year neurodevelopmental out-
come data in a concurrently tested group of healthy
term control children makes this conclusion premature.
It could be that the novel and highly sophisticated tech-
niques that were used to detect abnormal outcomes are
so sensitive as to give a high false positive rate and that
if a group of healthy term control infants were tested at
the same time, they too would have unexpectedly high
rates of abnormal outcomes. More importantly, there
are significant risks to a more aggressive screening and
treatment strategy. These include increased frequency of
blood sampling, use of formula supplementation, admis-
sion to the NICU and separation from the mother, com-
plications of intravenous catheters, and side effects of
any therapies used to raise glucose concentrations.
These risks must be balanced against the potential harm
due to asymptomatic hypoglycemia, progression to
symptomatic hypoglycemia, and delay in diagnosis and
treatment of serious metabolic disorders.
The authors also noted three important associations in
their data that should provide some caution with respect
to increasing glucose treatment thresholds and goals.
One is that newborns who did not have a plasma
glucose lower than 54 mg/dL (3.0 mmol/L) had worse
outcomes than those newborns who did. By CGMS data,
the average difference in glucose concentrations between
those with worse outcomes and those with better out-
comes was only 2.9 mg/dL (0.16 mmol/L). A second
important association noted was that those newborns
who had more time with plasma glucose concentrations
outside the range of 54–72 mg/dL (3.0–4.0 mmol/L) did
worse in terms of the highly sensitive neurodevelopmen-
tal outcomes than those who had more time within this
concentration range. Clearly, these first two associations
are in conflict if one were to attempt to change clinical
practice based on these observations. Most likely these
conflicting associations show that sicker neonates are
more metabolically unstable and have worse two year
neurodevelopmental outcomes, not that the increased
glucose concentration variability necessarily caused the
worse outcomes – though this possibility cannot be
excluded.
The final important association identified is that, of
the hypoglycemic newborns, those with worse outcomes
had a steeper rise in their glucose concentrations after
treatment with dextrose. This brings up the possibility
that in these at-risk asymptomatic newborns with low
glucose concentrations, when one decides to commence
therapy with intravenous dextrose, it is reasonable to
simply start the patient on a continuous glucose infusion
rate and not precede this with the traditional 200 mg/kg
intravenous dextrose bolus. Previous studies have shown
that within 20–30 min hypoglycemic newborns treated
without the 200 mg/kg bolus dextrose and only a con-
tinuous infusion of dextrose achieve glucose concentra-
tions similar to those treated with the dextrose bolus
followed by the same continuous dextrose infusion rate
[35]. Given that no study has shown that treatment of
asymptomatic hypoglycemia in these patients, no matter
how rapid, improves outcomes, it seems that avoiding
the steeper rise in glucose concentrations which were
associated with worse outcomes in the McKinlay, et al.
study is warranted. Other important points to consider
when evaluating this study are that severe and symptom-
atic hypoglycemia was rare. Similarly, hyperglycemia also
was rare, as only three patients had a plasma glucose
concentration greater than 144 mg/dL (8 mmol/L). It
also should be emphasized again that the only patients
studied were those who were asymptomatic and late
preterm, LGA, SGA/IUGR, and IDM infants [34]. The
conclusions, including the abandonment of the 200 mg/
kg dextrose bolus, cannot necessarily be extrapolated to
other groups, especially those with symptomatic
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hypoglycemia or a defined or suspected serious meta-
bolic hypoglyyemia disorder, such as congenital hyper-
insulinemic hypoglycemia or genetic conditions that
lead to excessive glucose utilization (fatty acid oxidation
disorders) or insufficient glucose production (hypopituit-
arism). Nevertheless, abandoning the dextrose bolus
might be beneficial in infants of diabetic mothers and
those with hyperinsulin-like conditions who respond to
rapid increases in glucose concentration with excessive
insulin secretion, potentially establishing a rebound
hypoglycemia if the continuous dextrose infusion is not
high enough.
Conclusions
Unfortunately, no recently published studies define
one ideal strategy to diagnose and appropriately treat
potentially damaging low glucose concentrations in
neonates. In order to determine the best management
strategy, a randomized trial comparing two different
strategies with appropriate long term follow up is
required, as proposed by Boluyt, et al. in 2006 [46].
Continued use of CGMS as a research tool to demon-
strate the impact of different glycemic patterns on long
term outcomes in hypoglycemia newborns will be very
helpful in this type of study [34, 43]. However, short of
this type of study we can look at recently published in-
formation and consider two potential changes in how
neonatal hypoglycemia is managed (Table 1). One is
consideration of dextrose gel as part of a treatment
protocol for neonatal hypoglycemia. The second is
abandonment of the 200 mg/kg intravenous dextrose
bolus for the treatment of asymptomatic, hypoglycemic
late preterm, LGA, SGA/IUGR, and IDM newborns.
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